[Retracted] Research Progress of B-Cell Lymphoma/Leukemia-2 Inhibitor Combined with Azacytidine in the Targeted Therapy of Acute Myeloid Leukemia

Table 3

Comparison of reported results of azacytidine and B-cell lymphoma/leukemia-2 inhibitors in the treatment of MDS/AML.

Test code name	Number	Of patients of median age pa		Total response rate/%	Median survival time/month
		/years	/people
This article investigates	AML/MDS	63	31	72.0	8.5
AZA-001	High-risk MDS	70	179	29.0	24.5
AZA-AML-001	265 years old AML	75	241	27.8	10.8
CCO	High-risk MDS/AML	74	1101	28.0	11.6
Pleyer	High-risk MDS/AML	73	302	48.0	9.6